Salvador
Martín Algarra
Consultor Médico
Alfonso
Berrocal Jaime
Publicaciones en las que colabora con Alfonso Berrocal Jaime (21)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583
-
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Clinical and Translational Oncology
2021
-
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598
2019
-
A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain
Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1754-1762
-
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
Oncologist, Vol. 24, Núm. 10, pp. 1375-1383
2017
-
Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study
Medicine, Vol. 96, Núm. 52, pp. e9523
-
Highlights of the season 2016-2017 by the Spanish Melanoma Group (GEM)
Annals of Translational Medicine, Vol. 5, Núm. 19
-
Infomelanoma 2020: An online digital application designed to assist health professionals for melanoma treatment
Annals of Translational Medicine, Vol. 5, Núm. 19, pp. 1-9
-
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768
-
Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)
Annals of Translational Medicine, Vol. 5, Núm. 19
-
Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)
Annals of Translational Medicine, Vol. 5, Núm. 19
2016
-
GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases
Annals of Oncology, Vol. 27, pp. vi383
-
Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02
Annals of Oncology, Vol. 27, pp. vi377
-
Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience
Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1147-1157
-
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
Melanoma Research, Vol. 26, Núm. 3, pp. 278-283
2015
-
Immune checkpoint inhibitors: Therapeutic advances in melanoma
Annals of Translational Medicine, Vol. 3, Núm. 18
-
Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma
European Journal of Dermatology, Vol. 25, Núm. 5, pp. 392-403
2014
-
Guidelines for biomarker testing in metastatic melanoma: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 362-373
-
Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations
Advances in Therapy, Vol. 31, Núm. 9, pp. 945-960
-
Recomendaciones para la determinación de biomarcadores en el melanoma metastásico. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia